RedHill Biopharma (RDHL) Treats Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Tweet Send to a Friend
RedHill Biopharma Ltd. (NASDAQ: RDHL) today announced that the last patient enrolled in the Phase III study with BEKINDA® 24 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
